- CH₣201.33m
- CH₣354.67m
- CH₣0.99m
- 29
- 20
- 50
- 23
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.75 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 1,540.37 | ||
| Price to Sales | 203.68 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4.01% | ||
| Return on Equity | 5.91% | ||
| Operating Margin | -2054.54% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CH₣m | 0.51 | 0.4 | 0.81 | 1.03 | 0.99 | 0.8 | n/a | 17.71% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +1100.03 | +140.53 | -77.2 | +5.56 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Xlife Sciences AG is a Switzerland-based biotechnology company. The Company focuses on investing in technologies in the life science industry. It supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. The Company offers its investors direct access to the further development of technologies at a very early stage. The Company cooperates with industrial partners and universities.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 20th, 2013
- Public Since
- September 30th, 2019
- No. of Employees
- 17
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
SIX Swiss Exchange- Shares in Issue
- 5,703,292
- Address
- Talacker 35, ZUERICH, 8001
- Web
- https://www.xlifesciences.ch/
- Phone
- +41 443858460
- Auditors
- BDO AG
Upcoming Events for XLS
Half Year 2024 Xlife Sciences AG Earnings Release
Similar to XLS
Addex Therapeutics
SIX Swiss Exchange
BACHEM HOLDING AG
SIX Swiss Exchange
Basilea Pharmaceutica AG Allschwil
SIX Swiss Exchange
BB Biotech AG
SIX Swiss Exchange
Evolva Holding
SIX Swiss Exchange
FAQ
What is the Xlife Sciences AG share price?
As of Today at 19:31 UTC, shares in Xlife Sciences AG are trading at CH₣35.30. This share price information is delayed by 15 minutes.
How has the Xlife Sciences AG share price performed this year?
Shares in Xlife Sciences AG last closed at CH₣35.30 and the price had moved by -3.02% over the past 365 days. In terms of relative price strength the Xlife Sciences AG share price has underperformed the FTSE Global All Cap Index by -13.46% over the past year.
What are the analyst and broker recommendations for Xlife Sciences AG?
The overall consensus recommendation for Xlife Sciences AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Xlife Sciences AG dividend yield?
Xlife Sciences AG does not currently pay a dividend.
Does Xlife Sciences AG pay a dividend?
Xlife Sciences AG does not currently pay a dividend.
When does Xlife Sciences AG next pay dividends?
Xlife Sciences AG does not currently pay a dividend.
How do I buy Xlife Sciences AG shares?
To buy shares in Xlife Sciences AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Xlife Sciences AG?
As of the previous close price of CH₣35.30, shares in Xlife Sciences AG had a market capitalisation of CH₣201.33m.
Where are Xlife Sciences AG shares listed?
Here are the trading details for Xlife Sciences AG:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: XLS
What kind of share is Xlife Sciences AG?
Based on an overall assessment of its quality, value and momentum Xlife Sciences AG is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Xlife Sciences AG share price forecast for 2024?
The analyst consensus target price for shares in Xlife Sciences AG is CH₣67.96. That is 92.52% above the last closing price of CH₣35.30.
Analysts covering Xlife Sciences AG currently have a consensus Earnings Per Share (EPS) forecast of -CH₣0.54 for the next financial year.
What is the trend in the Xlife Sciences AG share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Xlife Sciences AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -18.71%.
As of the last closing price of CH₣35.30, shares in Xlife Sciences AG were trading -14.75% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Xlife Sciences AG PE Ratio?
The Xlife Sciences AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CH₣35.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Xlife Sciences AG?
We do not have data on Xlife Sciences AG's directors